[go: up one dir, main page]

WO2006123097A3 - Improved expression elements - Google Patents

Improved expression elements Download PDF

Info

Publication number
WO2006123097A3
WO2006123097A3 PCT/GB2006/001656 GB2006001656W WO2006123097A3 WO 2006123097 A3 WO2006123097 A3 WO 2006123097A3 GB 2006001656 W GB2006001656 W GB 2006001656W WO 2006123097 A3 WO2006123097 A3 WO 2006123097A3
Authority
WO
WIPO (PCT)
Prior art keywords
genetic elements
expression elements
improved expression
levels
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2006/001656
Other languages
French (fr)
Other versions
WO2006123097A2 (en
Inventor
David John Simpson
Steven Geraint Williams
Alistair Simpson Irvine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EMD Millipore Corp
Original Assignee
Serologicals Finance Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serologicals Finance Co filed Critical Serologicals Finance Co
Priority to EP06727026A priority Critical patent/EP1891223B1/en
Priority to AT06727026T priority patent/ATE494381T1/en
Priority to JP2008511772A priority patent/JP5080452B2/en
Priority to DE602006019422T priority patent/DE602006019422D1/en
Priority to CN2006800173095A priority patent/CN101208435B/en
Publication of WO2006123097A2 publication Critical patent/WO2006123097A2/en
Publication of WO2006123097A3 publication Critical patent/WO2006123097A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention relates to genetic elements capable of improving the levels of expression of operably-linked transcription units. In particular, said genetic elements are derived from the 5' untranslated regions of ribosomal protein genes and may comprise a CpG island. Also provided are vectors and host cells comprising said genetic elements and methods of use to obtain high levels of recombinant gene expression.
PCT/GB2006/001656 2005-05-17 2006-05-09 Improved expression elements Ceased WO2006123097A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP06727026A EP1891223B1 (en) 2005-05-17 2006-05-09 Improved expression elements
AT06727026T ATE494381T1 (en) 2005-05-17 2006-05-09 IMPROVED EXPRESSION ELEMENTS
JP2008511772A JP5080452B2 (en) 2005-05-17 2006-05-09 Improved expression elements
DE602006019422T DE602006019422D1 (en) 2005-05-17 2006-05-09 IMPROVED EXPRESSION ELEMENTS
CN2006800173095A CN101208435B (en) 2005-05-17 2006-05-09 Improved expression elements

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0509965.0 2005-05-17
GBGB0509965.0A GB0509965D0 (en) 2005-05-17 2005-05-17 Improved expression elements
US68227705P 2005-05-18 2005-05-18
US60/682,277 2005-05-18

Publications (2)

Publication Number Publication Date
WO2006123097A2 WO2006123097A2 (en) 2006-11-23
WO2006123097A3 true WO2006123097A3 (en) 2007-01-11

Family

ID=34708242

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/001656 Ceased WO2006123097A2 (en) 2005-05-17 2006-05-09 Improved expression elements

Country Status (9)

Country Link
US (2) US7632661B2 (en)
EP (2) EP2295589A1 (en)
JP (1) JP5080452B2 (en)
CN (1) CN101208435B (en)
AT (1) ATE494381T1 (en)
DE (1) DE602006019422D1 (en)
ES (1) ES2358680T3 (en)
GB (1) GB0509965D0 (en)
WO (1) WO2006123097A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101942442B (en) 2003-06-24 2013-10-09 建新公司 Novel beta-actin and rps21 promoters and uses thereof
WO2008044869A1 (en) * 2006-10-10 2008-04-17 Viromed Co., Ltd. Expression vectors with improved safety
EP2109674A2 (en) * 2007-01-08 2009-10-21 Millipore Corporation High expression cell line that eliminates gene amplification
WO2009155950A1 (en) 2008-06-27 2009-12-30 King Faisal Specialist Hospital And Research Centre Cloning-free method of generating transcriptionally and post-transcriptionally controllable expression active linear reporter constructs
WO2010008543A2 (en) * 2008-07-15 2010-01-21 Trustees Of Dartmouth College Molecular signatures for diagnosing scleroderma
EP2411007A4 (en) * 2009-03-27 2012-12-05 Uab Research Foundation MODULATION OF MEDIATION TRANSLATION BY IRES SEQUENCES
DK2443239T3 (en) 2009-06-15 2016-02-15 Cellagenics B V New stringent selection markers
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
EP2611915B1 (en) * 2010-09-01 2015-04-15 Cellagenics B.V. Nucleic acid fragments from a ribosomal protein promoter for enhancing gene expression
RU2014121383A (en) * 2011-11-28 2016-01-27 Дайити Санкио Компани, Лимитед COMING FROM HUMAN GENE
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
ES2969742T3 (en) 2012-03-27 2024-05-22 CureVac SE Artificial nucleic acid molecules for enhanced expression of proteins or peptides
US20150105433A1 (en) * 2012-04-27 2015-04-16 The Uab Research Foundation TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM
US11254951B2 (en) 2014-12-30 2022-02-22 Curevac Ag Artificial nucleic acid molecules
AU2014375402B2 (en) * 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
EP3842537A1 (en) * 2013-12-30 2021-06-30 CureVac AG Artificial nucleic acid molecules
MX377591B (en) * 2014-10-15 2025-03-10 Amgen Inc Promoter and regulatory elements for improved expression of heterologous genes in host cells
EP3344034A1 (en) * 2015-09-02 2018-07-11 Regeneron Pharmaceuticals, Inc. Rodent model of prostate cancer
EP3589329B1 (en) 2017-05-11 2022-10-12 Zentrum für Forschungsförderung in der Pädiatrie GmbH Concept for the treatment of monogenetic disorders
US20210317498A1 (en) 2018-08-09 2021-10-14 Daiichi Sankyo Company, Limited PROMOTER of Hspa8 GENE
CN111249457A (en) * 2020-04-13 2020-06-09 吉林大学 Medical use of ribosomal protein SA antibodies in immunomodulation
CN119013400A (en) 2022-04-26 2024-11-22 第一三共株式会社 Promoter of Eno1 Gene
CN116064624A (en) * 2022-09-15 2023-05-05 思鹏生物科技(苏州)有限公司 Method for promoting stable expression of vector by using RPL gene and its functional gene
CN116064663A (en) * 2022-09-15 2023-05-05 思鹏生物科技(苏州)有限公司 Method for promoting stable expression of vector by using RPS gene and its functional gene

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005393A2 (en) * 1998-07-21 2000-02-03 Cobra Therapeutics Limited A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)
WO2002081677A2 (en) * 2001-04-05 2002-10-17 Ml Laboratories Plc Improved gene expression
WO2002099089A1 (en) * 2001-06-04 2002-12-12 Corixa Corporation Compositions and methods for high-level, large-scale production of recombinant proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583009A (en) * 1992-12-08 1996-12-10 University Of Washington Method of preparing recombinant proteins in transgenic animals containing metallothionein gene elements that bestow tissue-independent copy number-dependent, position-indepedent gene expression
US5610053A (en) * 1993-04-07 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
US6110666A (en) 1994-06-09 2000-08-29 Medical Research Council Locus control subregions conferring integration-site independent transgene expression abstract of the disclosure
DE19539493A1 (en) * 1995-10-24 1997-04-30 Thomae Gmbh Dr K Strong homologous promoter from hamster
DK0918874T3 (en) 1996-08-16 2001-05-14 Medical Res Council Self-replicating episomal expression vectors that provide tissue-specific gene expression
US6689606B2 (en) * 1998-07-21 2004-02-10 M.L. Laboratories Plc Polynucleotide
KR100996016B1 (en) 2000-09-20 2010-11-22 밀리포어 코포레이션 Polynucleotide
GB0022995D0 (en) * 2000-09-20 2000-11-01 Cobra Therapeutics Ltd Polynucleotide
US7812148B2 (en) 2001-04-05 2010-10-12 Millipore Corporation Vectors comprising CpG islands without position effect varigation and having increased expression
US7604989B2 (en) 2001-07-10 2009-10-20 Johns Hopkins University Inhibition of apoptosis process and improvement of cell performance
US7384744B2 (en) * 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005393A2 (en) * 1998-07-21 2000-02-03 Cobra Therapeutics Limited A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)
WO2002081677A2 (en) * 2001-04-05 2002-10-17 Ml Laboratories Plc Improved gene expression
WO2002099089A1 (en) * 2001-06-04 2002-12-12 Corixa Corporation Compositions and methods for high-level, large-scale production of recombinant proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 15 May 2003 (2003-05-15), "HO15I23S HO Hordeum vulgare cDNA clone HO15I23 5-PRIME, mRNA sequence.", XP002400750, retrieved from EBI accession no. EM_PRO:CD057580 Database accession no. CD057580 *
DATABASE EMBL [online] 5 September 2001 (2001-09-05), "Mus musculus ribosomal protein S3 (Rps3) gene, complete cds; and U15a snoRNA and U15b snoRNA genes, complete sequence.", XP002400749, retrieved from EBI accession no. EM_PRO:AY043296 Database accession no. AY043296 *
PONGER LOIC ET AL: "CpGProD: Identifying CpG islands associated with transcription start sites in large genomic mammalian sequences", BIOINFORMATICS (OXFORD), vol. 18, no. 4, April 2002 (2002-04-01), pages 631 - 633, XP002400746, ISSN: 1367-4803 *
TALBOT D ET AL: "THE 5' FLANKING REGION OF THE RAT LAP (C/EBPBETA) GENE CAN DIRECT HIGH-LEVEL, POSITION-INDEPENDENT, COPY NUMBER-DEPENDENT EXPRESSION IN MULTIPLE TISSUES IN TRANSGENIC MICE", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 22, no. 5, 11 March 1994 (1994-03-11), pages 756 - 766, XP000867294, ISSN: 0305-1048 *
WILLIAMS STEVEN ET AL: "CpG-island fragments from the HNRPA2B1/CBX3 genomic locus reduce silencing and enhance transgene expression from the hCMV promoter/enhancer in mammalian cells", BMC BIOTECHNOLOGY, BIOMED CENTRAL LTD. LONDON, GB, vol. 5, no. 1, 3 June 2005 (2005-06-03), pages 17, XP021005966, ISSN: 1472-6750 *

Also Published As

Publication number Publication date
CN101208435B (en) 2012-05-23
WO2006123097A2 (en) 2006-11-23
EP1891223A2 (en) 2008-02-27
US7632661B2 (en) 2009-12-15
GB0509965D0 (en) 2005-06-22
US20080097088A1 (en) 2008-04-24
ATE494381T1 (en) 2011-01-15
EP2295589A1 (en) 2011-03-16
ES2358680T3 (en) 2011-05-12
JP5080452B2 (en) 2012-11-21
US20100015107A1 (en) 2010-01-21
CN101208435A (en) 2008-06-25
EP1891223B1 (en) 2011-01-05
DE602006019422D1 (en) 2011-02-17
JP2008539781A (en) 2008-11-20

Similar Documents

Publication Publication Date Title
WO2006123097A3 (en) Improved expression elements
WO2003080807A8 (en) Compositions and methods for suppressing eukaryotic gene expression
WO2007149852A3 (en) Modified factor viii and factor ix genes and vectors for gene therapy
WO2008070357A3 (en) Smoothened polypeptides and methods of use
WO2004037977A3 (en) Use of chimeric nucleases to stimulate gene targeting
EP2339016A3 (en) Enhanced protein expression in bacillus
WO2008084115A3 (en) Lactococcus promoters and uses thereof
EP2336305A3 (en) Cloning of cytochrome P450 genes from Nicotiana
WO2002024234A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
DE60038011D1 (en) IMPROVEMENT OF THE IMMUNE RESPONSE AS APPLIED IN VACCINATION AND GENE THERAPY
WO2020186207A3 (en) Non-viral dna vectors and uses thereof for expressing fviii therapeutics
AU2004269200A8 (en) Enhancing accumulation of heterologous polypeptides in plant seeds through targeted suppression of endogenous storage proteins
WO2002048329A3 (en) Membrane derived caspase-3, compositions comprising the same and methods of use therefor
WO2003007699A3 (en) Transcription factors of cereals
WO2002036792A3 (en) Dna expression vectors
WO2005010149A3 (en) Subgroup b adenoviral vectors for treating disease
WO2005079367A3 (en) Schizochytrium fatty acid synthase (fas) and products and methods related thereto
WO2007008486A3 (en) Aav vectors encoding superoxide dismutase
WO2006053245A3 (en) Retroviral vectors with introns
WO2006047728A3 (en) Bmp gene and fusion protein
WO2006076628A3 (en) Compositions comprising promoter sequences and methods of use
WO2007044627A3 (en) Compositions and methods for delivery of interfering rna
WO2006122971A3 (en) Treatment of disease using an improved regulated expression system
WO2007127347A3 (en) An isolated dna fragment of the sparc human promoter and its use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008511772

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 8592/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200680017309.5

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006727026

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWP Wipo information: published in national office

Ref document number: 2006727026

Country of ref document: EP